RxDoctor Payments DataLook up a doctor →

Ahmed Awad, DO

Nephrology · Kansas City, MONPI 1740245182

Payments from drug & device makers

$12,355,814in general payments, 2019–2025

Across 3,542 payments — averaging $3488.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$6.1M
  • Akebia Therapeutics Inc$1.4M
  • AstraZeneca$1.2M
  • Bayer$888K
  • Boehringer Ingelheim$639K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$401K
  • plus $1.6M from 42 others
$30,155in research payments, 2019–2025

Across 12 payments — averaging $2512.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$30K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,355,814 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$225,476
Medicare patients
463
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →